Large 'pay for delay' fine imposed by CMA

Large 'pay for delay' fine imposed by CMA


On the 12th of February 2016, the UK Competition and Markets Authority fined GlaxoSmithKline and the successor companies to Alpharma Limited around 45m in total for breaches of Chapter I of the Competition Act 1998, the prohibition against anti-competitive agreements. The case shows the continued danger in pharmaceuticals reaching settlement agreements in IP disputes with generic drug providers.



from Biotech News